Background: Lupin kernel flour (LKF) is a novel food ingredient that is high in protein and fibre. We have previously shown that partial substitution of refined wheat-derived carbohydrate in bread with protein and fibre from LKF can reduce appetite and energy intake acutely. In addition, several studies have suggested that lupin may reduce cholesterol concentrations and benefit glucose and insulin metabolism. Aim: The aim of this study was to investigate the effects on body weight and composition and blood lipids, glucose and insulin of an ad libitum LKF-enriched diet higher in dietary protein and fibre. Subjects and methods: A total of 88 overweight and obese men and women were recruited for a 16-week parallel-design randomized controlled trial. Participants replaced 15-20% of their usual daily energy intake with white bread (control) or LKF-enriched bread (lupin) in an ad libitum diet. Measurements of body weight and composition, and fasting blood biochemical measurements were performed at baseline and 16 weeks. The primary analysis included 74 participants (37 per group) who completed the intervention. Results: At baseline, mean ( ± s.d.) body mass index and total cholesterol were 30.6 ± 3.5 kg m À2 and 5.37 ± 0.94 mmol l À1 , respectively. Estimated (mean between-group difference (95% confidence interval)) protein (13.7 (2.28, 25.0) g per day) and fibre (12.5 (8.79, 16.2) g per day) intakes were higher during the intervention with lupin than with control. For lupin relative to control, the net effects on body weight (À0.4 (À1.3, 0.6) kg), fat mass (À0.5 (À1.1, 0.2) kg) and percentage (À0.5 (À1.1, 0.1)%), plasma leptin (À1.66 (À4.91, 1.59) ng ml À1 ) and adiponectin (0.20 (À0.73, 1.13) mg l À1 , as well as serum total cholesterol (À0.08 (À0.38, 0.22) mmol l À1 ), triglycerides (0.09 (À0.10, 0.21) mmol l À1 ), glucose (0.10 (À0.11, 0.30) mmol l À1 ) and insulin (0.40 (À1.20, 2.00) mU l À1 ) were not significant. Conclusions: This study does not support the proposal that an ad libitum diet enriched in LKF resulting in moderate changes in both protein and fibre intakes can benefit body weight and composition or fasting blood lipids, glucose and insulin concentrations in overweight men and women with mildly elevated total cholesterol concentrations.
Introduction
Lupin is a grain legume. Lupin kernel flour (LKF), which is derived from the endosperm of lupin, contains 40-45% protein, 25-30% fibre, as well as negligible sugar and starch. 1 It is commonly used as a minor food ingredient in various baked foods. At higher inclusion levels, LKF can significantly alter the macronutrient composition of high-carbohydrate foods. For example, we have shown that incorporation of LKF into bread can increase protein and fibre and reduce carbohydrate content, with little change in product acceptability. 2 The nutrient composition of a diet may have an important role in influencing satiety and energy intake acutely and ultimately body weight in the longer term. In this regard, dietary fibre and protein seem to be the most satiating nutrients. There is now convincing evidence that increasing dietary fibre intake, [3] [4] [5] and dietary protein compared with carbohydrate, 6, 7 can increase satiety and reduce energy intake acutely in the short term. There is also evidence that these acute and short-term effects of fibre and protein on appetite may translate into benefits on body weight in the longer term. Many randomized controlled trials have investigated whether high-fibre diets 4 or high protein-low carbohydrate 8 diets result in greater weight loss during longer-term energy restriction. Results obtained from these trials are inconclusive, but suggest that both high-fibre and high-protein diets may enhance weight loss. 4, 8 Fewer trials
have assessed the longer-term effects on body weight of altering the fibre 9, 10 or protein 11, 12 content of ad libitum diets, and clear evidence of effects in this context is still to be established. Furthermore, the potential for additive benefits on weight loss of altering both protein and fibre has yet to be evaluated.
We recently investigated the acute effects of LKF on appetite and energy intake. 2 Increasing the protein and fibre content of bread using LKF, at the expense of wheat-derived carbohydrate, resulted acutely in higher satiety and lower energy intake. Consumption of LKF-enriched bread resulted in significantly lower energy intake during a meal by B30% and at a subsequent meal by B15%. These results are consistent with those of an earlier study which demonstrated elevated post-meal satiety using an isolated fibre fraction derived from the lupin kernel. 13 If acute effects on satiety and energy intake are sustained during longer-term regular consumption of LKF-enriched bread, it could translate into significant benefits on body weight. Dyslipidaemia 14 and impaired glucose metabolism 15 are major risk factors for cardiovascular disease. Plant proteins and soluble fibres in the diet may provide benefits to the serum lipid and lipoprotein profile, [16] [17] [18] [19] as well as to glucose and insulin metabolism. 20, 21 In addition, results obtained from several animal studies suggest cholesterol-lowering effects of lupin. Cholesterol lowering has been observed in chickens 22 and pigs 23 fed whole lupin grain. Other data suggest that protein and fibre isolates from lupin may improve serum lipids. In rats, a lupin protein isolate significantly reduced plasma total cholesterol concentrations by 21%. 24 In humans, a lupin fibre isolate, providing an additional 17-30 g per day of dietary fibre, reduced total and low-density lipoprotein (LDL)-cholesterol concentrations by B5%. 25 Results of acute studies also suggest the potential for benefit of lupin-enriched foods on blood glucose metabolism. 2, 26 We have previously shown that consumption of LKF-enriched bread significantly reduced postprandial glucose and insulin in comparison with matching energy from white bread. 2 Hall et al. 26 found that LKF-enriched bread significantly reduced postprandial glucose in comparison with a matching carbohydrate load from white bread. The effects of the combination of lupin protein and fibre on fasting lipids, glucose and insulin have yet to be examined in a longer-term randomized controlled trial in humans. Therefore, the aim of this study was to investigate the metabolic effects of an ad libitum LKF-enriched diet higher in dietary protein and fibre in overweight men and women with mildly elevated total cholesterol concentrations. This was brought about through the regular consumption of bread in which wheat flour was partially substituted with LKF. Our hypothesis was that regular consumption of a LKF-enriched diet would benefit body weight and composition, fasting blood lipid and lipoprotein concentrations, as well as fasting blood glucose and insulin concentrations.
Subjects and methods

Subjects
Overweight and obese men and women were recruited for the trial. Non-smokers aged 20-70 years with a body mass index (BMI) of 25-35 kg m À2 at the time of screening were recruited from the general population. Exclusion criteria included history of cardiovascular or peripheral vascular disease, diabetes, fasting plasma glucose concentrations X5.6 mmol l
À1
, history of asthma, renal disease, liver disease or gout, psychiatric illness, history of major gastrointestinal problems, other major illnesses such as cancer, uncontrolled hypertension (systolic blood pressure 4150 mm Hg or diastolic 495 mm Hg), use of more than two antihypertensive agents, a change in antihypertensive, lipid-lowering or other medication within the previous 3 months, women who were pregnant or intended to become pregnant, history of food allergies, current weight loss, as well as alcohol intake 4200 g per week for women and 4300 g per week for men.
All participants provided written informed consent, and the procedures followed were in accordance with institutional guidelines. The trial was approved by the University of Western Australia Human Ethics Committee, and registered at the Australian New Zealand Clinical Trials Registry as ACTRN12606000034538.
Study design
A total of 88 participants were recruited for the randomized controlled parallel-design trial of 16-weeks duration. Participants were randomly assigned using computer-generated random numbers concealed in opaque envelopes to one of the two groups: control or lupin. The random number procedure was conducted by a biostatistician who did not have any contact with the volunteers. Participants maintained their usual diet, physical activity and medication regimen during a baseline period of 2 weeks, which preceded randomization. Participants, in both groups, were then required to replace approximately 15-20% of their usual daily energy intake with bread, either control or lupin, for 16 weeks.
Control bread was a standard white bread. Lupin bread was formulated by substituting 40% of wheat flour usually present in white bread with LKF. Adjustments to the recipes for control and lupin bread were made to match breads for total fat and saturated, monounsaturated and polyunsaturated fat, protein derived from wheat (gluten) and sodium. 2 For a 9 MJ per day energy intake, the bread intake was B4 Â 32 and 4 Â 40 g slices of control and lupin bread per day, respectively. Participants and investigators were not blinded to treatment allocation because of obvious differences in colour and texture of the two bread types. Every 2 weeks, participants were supplied fresh sliced bread on the basis of the usual energy intake. This was then consumed fresh or was frozen before use. The bread provided replaced usual bread intake and, where necessary, other carbohydrate-rich foods such as pasta, rice and breakfast cereals. A dietitian counselled the participants at baseline on how to incorporate bread into their usual diet. Participants were instructed not to alter their food intake, apart from prescribed changes, and to maintain their usual level of physical activity. Medication remained as prescribed and did not change throughout the intervention. Participants were counselled by a dietitian every 2 weeks throughout the intervention to ensure maintenance of usual lifestyle and the required bread incorporation into the diet. The aim was to achieve mean between-group differences in protein, fibre and carbohydrate intakes of B15, 13 and À20 g per day, respectively, for lupin relative to control. All measurements were performed at baseline and at the completion of the 16-week intervention. Body weight was also assessed every 2 weeks throughout the intervention.
Dietary assessment
Dietary intake at baseline and during the final week of intervention was assessed by a qualified dietitian using a modified diet history questionnaire. 27 Participants described their usual daily eating pattern, including variations, with portion size estimated using food models. Dietary data were analysed using FoodWorks Professional 2007 (Xyris, Highgate Hill, Queensland, Australia) to determine average daily energy and macronutrient intake. Compliance with bread intake was assessed every 2 weeks using a daily bread intake record in which participants recorded the number of slices consumed each day throughout the study. If the bread intake was outside the prescribed level or if changes to the diet or lifestyle were reported, advice was provided on how these could be adjusted. If these could not be rectified or if they resulted in an inability to commit to the requirements of the study, the participant was withdrawn from the study.
Body weight and composition
At baseline and every 2 weeks throughout the study, body weight was determined using a Wedderburn digital scale (20-200 kg) (Wedderburn, Perth, Western Australia). Participants were weighed with minimal clothing without shoes and weight was recorded to the nearest 0.1 kg. Performing body weight measurements every 2 weeks allowed analysis of any differences in the rate of change in body weight over the 16-week intervention (slope of weight change). At baseline (week 0) and during the final week of intervention (week 16), body composition was measured with dual-energy X-ray absorptiometry (GE Lunar Prodigy, GE Lunar Corporation, Madison, WI, USA). The scanner was calibrated before each measurement session against the standard calibration block supplied by the manufacturer for possible baseline drift. A quality-control test to monitor the reproducibility and stability of data was also performed before each session using a spine phantom provided by the manufacturer. The value from the quality-control test was plotted on graphs, and the score of each measurement was required to be within 1.5% of the baseline result.
Participants were not required to fast, as food and fluid intake has minimal effects on dual-energy X-ray absorptiometry measurements of body composition. Participants were requested to dress in light clothing. They were placed in a supine position within the scan lines with their head 3 cm from the top border. Whole body fat mass, body fat percentage and fat-free mass were determined using the manufacturer's algorithm (Prodigy enCORE software 2004 v 8.50.093, GE Lunar Corporation). Android fat was estimated as the fat mass present in the area delineated by an upper horizontal border above the pelvis line at a position that was equivalent to 20% of the distance between the pelvis and the femoral neck, vertical borders lateral to the ribs and a lower border formed by the horizontal line passing through the top of the pelvis. Gynoid fat was estimated as the fat mass present in the area defined by the following demarcations: the upper boundary was positioned below the pelvis cut by 1.5 times the height of the android region; and the lower boundary was positioned at two times the height of the android region with the lateral boundaries as the outer leg lines. 28 Measurements were performed and analysed by the same operator. To avoid potential bias in the estimation of regional fat mass, for each participant, the cut positions used at baseline (week 0) were saved and used again at the end of intervention (week 16) scan.
Biochemistry
All biochemical analyses were performed in the PathWest laboratory at the Royal Perth Hospital, Western Australia. At baseline and at 16 weeks, blood samples were collected from Lupin, body weight and blood lipids JM Hodgson et al the antecubital fossa vein after a 12-h fast. The samples were centrifuged at 3000 r.p.m. at 4 1C for 10 min, and then stored at À80 1C until analysis. For all analyses, the samples were run in a single batch to reduce variability. Serum was analysed for total cholesterol, high-density lipoprotein (HDL)-cholesterol and triglycerides using routine analysis based on an enzymatic colorimetric test with a fully automated analyser (Roche Hitachi 917, Roche Diagnostics Australia Pty. Ltd., Castle Hill, New South Wales, Australia). LDL-cholesterol concentrations were calculated using the Friedewald formula. 29 The coefficient of variation (CV) for the measurement of total cholesterol, HDL-cholesterol and triglyceride assays was 2.5, 1.5 and 3.6%, respectively. Serum insulin concentrations were analysed using a chemiluminescent immunometric assay kit (IMMU-LITE 2000 Insulin, EURO/DPC Ltd., Gwynedd, UK), with a CV of 3.5%. Serum glucose was analysed from fresh serum samples using an ultraviolet test with a fully automated analyser (Roche Hitachi 917), with a CV of 2.1%. The homeostasis model assessment score was calculated using the following formula, 30 (Serum glucose (mmol l
À1
) Â Serum insulin (mU ml À1 )/22.5), to estimate changes in insulin sensitivity. Plasma leptin levels were analysed using human leptin enzyme immunoassay kits (Diagnostic Systems Laboratories, Webster, TX, USA). 31 The lowest level of detectable leptin by this assay was 0.5 ng ml
. The CV of the assay was 4.5%. Plasma adiponectin levels were analysed using human adiponectin enzyme immunoassay kits (Quantikine R&D, Minneapolis, MN, USA). 32 The lowest level of detectable adiponectin by this assay was 0.25 ng ml
. The CV of the assay was 6.5%. High-sensitivity C-reactive protein was measured using particle-enhanced immunonephelometry kits on a BN Systems analyser (Dade Behring Diagnostics, Lane Cove, New South Wales, Australia), with a CV of 4.5%.
Statistical analysis
Statistical analyses were performed using SPSS 15.0. software (SPSS, Chicago, IL, USA) or SAS 8.2 software (SAS Institute, Cary, NC, USA). The sample for this study was calculated on the primary outcome of body weight. With a ¼ 0.05, 40 participants per group provided 490% power to detect a 2-kg difference between groups. Secondary outcome measures included body fat mass, body fat percentage and fasting serum concentrations of cholesterol, triglycerides, glucose and insulin. We aimed to recruit 90 participants for the study to allow for an estimated 10% withdrawal rate over the 16-week intervention period. The primary analysis included participants who completed the intervention. Intention-totreat analysis was also performed using baseline values carried forward. For descriptive baseline data, results are presented as mean ± s.d. The baseline-adjusted end-of-intervention values and between-group differences are presented as mean (95% confidence interval). Body weight measurements performed every 2 weeks are presented as mean and s.e.m. Po0.05 was the level of significance in two-tailed testing. At baseline, characteristics of participants in the two groups were compared using the independent-samples t-test and the w 2 test for categorical variables. General linear models (analysis of covariance) were used to assess baseline-adjusted end-ofintervention between-group differences. Between-group differences in body weight change over time (slope) were analysed with random effects models in SAS using PROC MIXED.
Results
Participants and baseline characteristics A total of 88 participants were randomized to the trial. In all, 14 participants withdrew: 8 because they were unable to consume the required quantity of bread; 4 owing to an inability to commit to time requirements; 1 because of moving interstate; and 1 because of an unrelated medical problem requiring a change in medication. There were no reported adverse effects of eating either white bread or lupin bread during the 16-week study. A total of 74 participants, 37 in each group, completed the trial. Baseline characteristics, including gender, age, body weight and fasting total cholesterol and glucose concentrations were not significantly different between participants who completed the trial and those who withdrew. Characteristics at baseline of the participants are presented in Table 1 . The groups were well matched, and there were no significant differences in any of the variables between the groups at baseline.
Bread, energy and nutrient intakes
The estimated mean ( ± s.d.) energy intakes from all bread at baseline was 1182 ± 675 kJ per day and 1251 ± 925 kJ (P40.10), for the control and lupin groups, respectively. This equates to B3 Â 40 g slices per day. During the intervention, the mean ( ± s.d.) energy intakes from the assigned breads were 1551±194 and 1638±248 kJ per day (P40.10) in the control and lupin groups, respectively. Therefore, B75% of the energy from the assigned breads (lupin or control) replaced energy from usual bread intake.
Estimates of between-group differences in macronutrient intakes, for lupin relative to control, based on this bread intake alone are: protein, 16 g per day; fibre, 14 g per day; and carbohydrate, 17 g per day. Participants were instructed not to alter their diet apart from the prescribed changes in bread intake. On the basis of the dietary data collected, there was a higher protein (mean between-group difference (95% confidence interval): 13. 
Body weight and composition
The baseline-adjusted body weight and body composition measurements of participants in the control and lupin groups at the end of intervention, and the between-group differences are presented in Table 2 . There were no significant differences between treatment groups in body weight, fat mass, body fat percentage, fat-free mass, android and gynoid fat percentages. There were also no significant differences between treatment groups in body weight and composition in separate sub-group analyses according to gender (men and women) and baseline BMI values (BMI above and below 30 kg m
À2
). In addition, there was no significant difference in the rate of weight change (slope) during the 16 weeks between the control and the lupin groups (P ¼ 0.38; Figure 1 ). An intention-to-treat analysis performed using data obtained from all 88 participants randomized to the study did not alter the interpretation of these results.
Blood cholesterol and triglycerides, glucose and insulin, and leptin and adiponectin
The baseline-adjusted end-of-intervention fasting biochemical measurements are presented in Table 3 . For lupin relative to control, total cholesterol, LDL-cholesterol and triglycerides were not altered, but HDL-cholesterol was significantly . Glucose, insulin, homeostasis model assessment score, leptin, adiponectin and high-sensitivity C-reactive protein concentrations were also not altered, and there were no significant differences between treatment groups in these variables in separate sub-group analyses according to gender and baseline BMI (BMI above and below 30 kg m
À2
). An intention-to-treat analysis of the study performed using data obtained from all 88 participants randomized to the study did not alter the interpretation of these results.
Discussion
Our aim was to investigate the effects on body weight and composition, and blood lipids, glucose and insulin of an ad libitum lupin-enriched diet higher in dietary protein and fibre. To do this, the effects of regular consumption of LKF-enriched bread, higher in protein and fibre and lower in refined carbohydrate, were compared with standard white bread. Consumption of LKF-enriched bread did not significantly alter body weight or body composition, blood lipids, or glucose and insulin concentrations in a population of overweight men and women.
Benefits of high-protein, low-refined carbohydrate and high fibre-low glycaemic index diets on obesity have been proposed. 4, 7, 8, [33] [34] [35] [36] [37] Effects on appetite is a major mechanism put forward. [3] [4] [5] [6] [7] Available data suggest that nutrient composition of the diet is an important factor for controlling satiety and short-term energy intake. There is now convincing data to show that higher protein in comparison with carbohydrate, [3] [4] [5] and high fibre intakes 6, 7 are both more satiating.
The potential effects of longer-term regular consumption of increased protein 11, 12 or fibre 9,10 ad libitum diets remain unclear. A novel feature of the current trial is the use of LKF to increase both protein and fibre intake at the expense of refined carbohydrate. We previously showed that consumption of LKF-enriched bread compared with white bread results in lower energy intake within and at a subsequent meal, 2 which is consistent with results obtained from other acute studies. If these effects were to occur consistently during regular consumption of LKF-enriched bread, then significant weight loss of 42 kg over a period of 16 weeks would have been expected. However, in the current study, body weight was lower in the lupin group in comparison with the control group by only 0.4 kg, which was not significant. The study was powered to show differences in body weight of 2 kg. If the observed trend was to continue beyond 4 months, there may be a 2-kg weight difference within 2 years. Longer-term studies are required to confirm this observed trend. The lack of effect on body weight and body composition may have several possible explanations. Most previous trials using either increased protein 8 or fibre 4 diets have investigated effects in a setting of energy restriction. Very few trials have investigated effects using an ad libitum diet. Benefits on body weight of increased fibre 9,10 and protein 11, 12 intakes in ad libitum diets have been reported. However, the amount of protein and fibre and type of fibre in the diet may be important. The increase in protein in the lupin group was relatively small in comparison with other intervention studies that have shown a beneficial effect on weight loss in the ad libitum 11, 12 or the energy-restricted setting. 8 The Table 3 Mean baseline-adjusted end-of-intervention fasting biochemical measurements and between-group differences of participants in the control and lupin groups a P-value is for baselineadjusted end-of-intervention differences analysed using general linear models (analysis of covariance).
b Values are baseline-adjusted mean or mean between-group difference (95% confidence intervals). Lupin, body weight and blood lipids JM Hodgson et al difference in protein intake in the current study was B4% of energy intake or 13.7 g per day, whereas most previous trials have used differences of 410% of energy. 8, 11, 12 However, this increase in protein intake was concurrent with a significant increase in dietary fibre intake. The increase in fibre intake in our study (12.5 g per day) was comparable with other intervention studies 4 and would be regarded as substantial, although the nature of the dietary fibre may be important. Studies of higher-fibre ad libitum diets showing weight loss have used isolated soluble fibres. 9, 10 The dietary fibre present in LKF derived from Lupinus angustifoliusFthe species used in this studyFis primarily insoluble (B70%). About 10% is present as soluble fibre (B1.25 g per day) and a further 20% as oligosaccharides. 1, 38, 39 Furthermore, given the demonstrated effects of lupin fibre 13 and flour 2 to increase satiety, it remains uncertain whether an effect of fibre on satiety is an important mechanism for longer-term benefits of high-fibre diets on body weight. Signals affecting appetite acutely may influence energy intake over the longer term. We previously showed that LKF-enriched bread significantly suppressed the 3 h postmeal plasma ghrelin response. 2 Ghrelin is an appetiteregulating peptide released from the stomach which acts centrally to stimulate food intake. 40 Differences between short-and long-term appetite regulation may have contributed to the observed results. Leptin is a protein hormone that has a key role in regulating energy intake and energy expenditure, including appetite in the longer term. 41 Adiponectin is a protein hormone that modulates a number of metabolic processes and is inversely associated with body fat. 42 The lack of effect on leptin and adiponectin concentrations in our study is consistent with the observed effects on body weight and body fat mass and percentage. It is possible that other environmental factors may be overriding any acute signals influencing satiety. Lupin-enriched foods have been previously shown to significantly reduce postprandial glucose and insulin. 2, 26 This study did not show any significant changes in fasting glucose, insulin and the homeostasis model assessment score, which can provide an indication of insulin sensitivity. In addition, we found no significant effect on plasma adiponectin, which is involved in glucose regulation. 43 However, it may be difficult to affect a reduction in fasting blood glucose or insulin concentrations in a population with normal levels at the outset, particularly in the short term and in the absence of any change in body weight and body fatness. Future studies should investigate effects in individuals with insulin resistance or type 2 diabetes.
To our knowledge, this is the first study to assess the effect of increased protein and fibre intake from lupin on blood lipids in humans. Lupin, relative to control resulted in lower HDL-cholesterol by 0.09 mmol l
À1
, but this could be explained by an increase in HDL-cholesterol from baseline to the end of intervention within the women in the control group by 0.14 mmol l
. The mechanism behind this apparent increase in HDL-cholesterol in the control group is uncertain. Overall, we found no significant benefit on the blood lipid and lipoprotein profile. The lack of effect of increased intake of both lupin protein and fibre on cholesterol and triglyceride concentrations may have several possible explanations.
Partial replacement of carbohydrate with protein in highprotein diets can improve the serum lipid and lipoprotein profile. 44 In this study, differences in protein and carbohydrate intakes between the groups were quite modest, and this was against the background of a diet that was reasonably high in protein. A source of protein heavily researched for its possible cholesterol-lowering action is soy. The protein structure and amino-acid composition of proteins from soy and lupin, both grain legumes, are similar. 45 Thus, it is predicted that soy and lupin protein would have a similar impact on blood cholesterol. A meta-analysis of human trials found that an average of 47 g per day of soy protein was associated with a 410% reduction in total and LDLcholesterol concentrations. 16 The current trial had 480%
power to detect a 10% difference between groups in total cholesterol concentrations. However, a more recent metaanalysis restricted to trials using supplements found that 20-106 g per day of soy protein resulted in only a 2-3% reduction in total and LDL-cholesterol concentrations. 17 Hyperlipidaemia has been suggested to be necessary to observe cholesterol lowering with soy, 16, 17 but the results of our sub-group analysis in participants with higher baseline cholesterol concentrations also indicated no effect in this population. Our results are therefore consistent with the recent meta-analysis of soy supplement trials. 17 The effects of dietary fibre on blood lipids and lipoproteins have been comprehensively investigated in randomized controlled trials. The source and structural characteristics of the fibre are important determinants of cholesterollowering activity. Meta-analyses and systematic reviews of 4100 randomized controlled trials show that B10 g per day of added soluble/viscous fibres results in an 8-10% reduction in total and LDL-cholesterol. 18, 19 There seems to be little additional benefit beyond 10 g per day. The magnitude of the effect is similar across the major sources of fibre used, including oat bran, psyllium, pectin and guar gum. Insoluble fibre from cereals has little impact on blood cholesterol concentrations. In this study, we found that a 12.5 g per day increase in fibre from LKF over a period of 16 weeks did not alter total and LDL-cholesterol concentrations. The lack of effect on blood lipids may be due to the physical and structural characteristics of the fibre provided, which was likely to be primarily insoluble. 1, 38, 39 In addition, the baseline total dietary fibre intake, which was B30 g per day, was higher than in most studies in which benefits of additional soluble fibre intake has been demonstrated. 18, 19 These observations may help to explain the apparent lack of cholesterol-lowering activity of the lupin kernel fibre in this study. A previous study 25 showed that a 17-30 g increase in fibre intake from isolated lupin kernel fibre significantly reduced Lupin, body weight and blood lipids JM Hodgson et al total cholesterol and LDL-cholesterol by B5% in healthy men. Another possible explanation for the seemingly inconsistent findings is that the increased fibre intake in our study was achieved through the incorporation of LKF-enriched bread into the daily diet rather than an isolated fibre. 25 The process of isolation of the lupin kernel fibre may have altered its properties or concentrated a more bioactive fraction. Isolation and purification of lupin kernel fibre can result in a higher ratio of soluble to insoluble fibre and higher viscosity and water-binding capacity than fibre naturally present in LKF. 46 In addition, the increase in lupin kernel fibre intake in the study by Hall et al. 25 was about twice of that in our study.
In conclusion, partial substitution of wheat flour in bread with LKF resulted in higher protein and fibre intake. However, no benefit on body weight and body composition, blood cholesterol, triglycerides, glucose and insulin concentrations were observed. Thus, this study does not support the hypothesis that, at least in the short term, moderate changes in both protein and fibre intakes derived from LKF in an ad-libitum diet can benefit body weight and composition, blood lipids, glucose or insulin concentrations in overweight men and women with mildly elevated total cholesterol concentrations. Future research should investigate whether LKF-enriched foods can aid in weight loss during energy restriction and the longer-term maintenance of weight loss. Trials that investigate effects of lupin protein and fibre in individuals with insulin resistance or type 2 diabetes are also warranted.
